No X-mas cards
We have decided to make a donation to the Stichting Contactgroep Leukemie project instead of sending Season's Greetings cards.
More news
- Kiadis Pharma signs license agreement with Hospira to commercialize ATIR™ in Europe and Asia - Partnership would advance innovative stem cell transplant product 4-1-2011
- Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™ 8-7-2010
- Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality 28-4-2010
- Kiadis Pharma announces enrollment of first patients in a multinational registration study for ATIR™ 29-11-2009
- Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at the 51st American Society of Hematology’s (ASH) Annual Meeting 5-11-2009
- Kiadis Pharma reports ATIR™ clinical data, further supporting its potential in mismatched bone marrow transplantations - ATIR™ data presented at the annual EBMT Presidential Symposium 8-4-2009
- Kiadis Pharma presents at the EBMT in Göteborg 31-3-2009
- Kiadis Pharma’s lead investigator presents results ATIR™ clinical trial at the BMT tandem meeting 6-2-2009
- Kiadis Pharma appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer 6-1-2009
- Kiadis Pharma announces appointment of Mark Skaletsky to its Supervisory Board 11-12-2008
